Cynosure Group LLC Cuts Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Cynosure Group LLC decreased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 16.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,269 shares of the medical instruments supplier’s stock after selling 656 shares during the period. Cynosure Group LLC’s holdings in LeMaitre Vascular were worth $301,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. New York State Teachers Retirement System boosted its position in shares of LeMaitre Vascular by 1.2% in the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock worth $755,000 after purchasing an additional 100 shares in the last quarter. Flputnam Investment Management Co. raised its stake in LeMaitre Vascular by 3.6% in the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock valued at $269,000 after buying an additional 102 shares during the last quarter. Norden Group LLC boosted its holdings in LeMaitre Vascular by 4.5% in the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock worth $218,000 after acquiring an additional 103 shares in the last quarter. Blue Barn Wealth LLC grew its stake in shares of LeMaitre Vascular by 4.4% during the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock worth $229,000 after acquiring an additional 104 shares during the last quarter. Finally, Shaker Investments LLC OH increased its holdings in shares of LeMaitre Vascular by 0.8% during the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock valued at $1,285,000 after acquiring an additional 112 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Stock Up 1.7 %

Shares of LMAT stock opened at $86.62 on Thursday. LeMaitre Vascular, Inc. has a 52-week low of $62.39 and a 52-week high of $109.58. The stock has a market cap of $1.95 billion, a PE ratio of 47.33, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. The business has a 50-day simple moving average of $92.25 and a 200-day simple moving average of $94.31.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. Sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.92%. The ex-dividend date was Thursday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 41.24%.

Insider Buying and Selling at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.